R&D Pipeline
| Product | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Pre-registration | Approved / Market |
|---|---|---|---|---|---|---|---|---|
| Elepsia™ XR (Levetiracetam ER) | Epilepsy |
|
||||||
| Xelpros™ (Latanoprost BAK Free) | Glaucoma |
|
||||||
| Salmeterol-Fluticasone DPI | Asthma / COPD |
|
||||||
| Baclofen GRS | Spasticity |
|
||||||
| Taclantis™ (PICN) | Cancer |
|
||||||
| Brimonidine OD | Glaucoma |
|
||||||
| SDN - 021 | Pain |
|
||||||
| SUN – K0706 | CML |
|
||||||
| SUN – 597 Topical | Steroid Responsive Dermatoses |
|
||||||
| SUN – K0706 | Parkinson’s Disease |
|
||||||
| Minocycline Topical | Acne |
|
||||||
| SCD – 044 | Autoimmune Disorders |
|
||||||
| SUN - K0954 | CML |
|
||||||
| SDP – 037 | Ocular Pain & Inflammation |
|
||||||
| Product | Elepsia™ XR (Levetiracetam ER) |
| Indication | Epilepsy |
| Phase in US | Pre-registration |
| Product | Xelpros™ (Latanoprost BAK Free) |
| Indication | Glaucoma |
| Phase in US | Pre-registration |
| Product | Salmeterol-Fluticasone DPI |
| Indication | Asthma / COPD |
| Phase in US | Phase 3 |
| Product | Baclofen GRS |
| Indication | Spasticity |
| Phase in US | Phase 3 |
| Product | Taclantis™ (PICN) |
| Indication | Cancer |
| Phase in US | Phase 3 |
| Product | Brimonidine OD |
| Indication | Glaucoma |
| Phase in US | Phase 2 |
| Product | SDN - 021 |
| Indication | Pain |
| Phase in US | Phase 1 |
| Product | SUN – K0706 |
| Indication | CML |
| Phase in US | Phase 1 |
| Product | SUN – 597 Topical |
| Indication | Steroid Responsive Dermatoses |
| Phase in US | Phase 1 |
| Product | SUN – K0706 |
| Indication | Parkinson’s Disease |
| Phase in US | Phase 1 |
| Product | Minocycline Topical |
| Indication | Acne |
| Phase in US | Preclinical |
| Product | SCD – 044 |
| Indication | Autoimmune Disorders |
| Phase in US | Preclinical |
| Product | SUN - K0954 |
| Indication | CML |
| Phase in US | Preclinical |
| Product | SDP – 037 |
| Indication | Ocular Pain & Inflammation |
| Phase in US | Preclinical |
